Amgen Stock: Analyst Estimates & Ratings

Core Insights - Amgen Inc. is a leading biopharmaceutical company with a market capitalization of $157.2 billion, focusing on innovative medicines for serious illnesses [1] Stock Performance - Over the past 52 weeks, Amgen's shares have declined by 7.5%, underperforming the S&P 500 Index, which gained 17.4% [2] - In 2025, Amgen's stock has risen by 12% year-to-date, but still lags behind the S&P 500's 16% YTD gains [2] - Compared to the Health Care Select Sector SPDR Fund, Amgen has underperformed over the past year but outperformed in the current year [3] Operational Challenges - Investor enthusiasm for Amgen has waned due to setbacks in its obesity-drug pipeline, particularly with the experimental candidate MariTide, which experienced higher-than-expected discontinuation rates in trials [4] - Legacy products are facing challenges from biosimilars and pricing pressures, impacting growth expectations [4] Earnings Expectations - For fiscal 2025, analysts project Amgen's EPS to grow by 6.3% year-over-year to $21.08, with a further increase of 1.7% to $21.43 in fiscal 2026 [5] - Amgen has a strong earnings surprise history, having beaten consensus estimates in the last four quarters [5] Analyst Ratings - Among 32 analysts covering Amgen, the consensus rating is a "Moderate Buy," with 11 "Strong Buy," 2 "Moderate Buy," 16 "Holds," 1 "Moderate Sell," and 2 "Strong Sells" [5] - The current rating configuration is less bullish than three months ago, when there were 12 "Strong Buy" ratings [6] - Oppenheimer's Jay Olson has reaffirmed a Buy rating on Amgen with a price target of $380, indicating a potential upside of 30% [6]